But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately.

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

Waystar upped its 2024 outlook and now expects total revenue to range between $926 million and $934 million, compared to ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...